Two Sigma Advisers’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,651,700
| Closed | -$1.62M | – | 739 |
|
|
2025
Q4 | $1.62M | Buy |
1,651,700
+644,300
| +64% | +$774K | ﹤0.01% | 1266 |
|
|
2025
Q3 | $1.27M | Buy |
1,007,400
+514,300
| +104% | +$555K | ﹤0.01% | 1343 |
|
|
2025
Q2 | $552K | Sell |
493,100
-293,900
| -37% | -$342K | ﹤0.01% | 1703 |
|
|
2025
Q1 | $622K | Sell |
787,000
-41,100
| -5% | -$50.4K | ﹤0.01% | 1687 |
|
|
2024
Q4 | $1.37M | Sell |
828,100
-99,140
| -11% | -$250K | ﹤0.01% | 1315 |
|
|
2024
Q3 | $3.25M | Sell |
927,240
-596,260
| -39% | -$2.32M | 0.01% | 860 |
|
|
2024
Q2 | $5M | Buy |
1,523,500
+85,800
| +6% | +$376K | 0.01% | 757 |
|
|
2024
Q1 | $10.6M | Sell |
1,437,700
-439,200
| -23% | -$2.72M | 0.02% | 523 |
|
|
2023
Q4 | $7.02M | Sell |
1,876,900
-55,900
| -3% | -$132K | 0.02% | 667 |
|
|
2023
Q3 | $4.1M | Buy |
1,932,800
+115,500
| +6% | +$383K | 0.01% | 834 |
|
|
2023
Q2 | $8.65M | Sell |
1,817,300
-53,500
| -3% | -$295K | 0.02% | 550 |
|
|
2023
Q1 | $10.7M | Buy |
1,870,800
+1,192,400
| +176% | +$7.19M | 0.03% | 533 |
|
|
2022
Q4 | $6.85M | Buy |
678,400
+629,400
| +1,284% | +$11.8M | 0.02% | 646 |
|
|
2022
Q3 | $1.1M | Buy |
49,000
+1,000
| +2% | +$28.9K | ﹤0.01% | 1473 |
|
|
2022
Q2 | $1.19M | Sell |
48,000
-26,500
| -36% | -$731K | ﹤0.01% | 1503 |
|
|
2022
Q1 | $2.89M | Sell |
74,500
-178,100
| -71% | -$6.9M | 0.01% | 1061 |
|
|
2021
Q4 | $14.8M | Sell |
252,600
-193,400
| -43% | -$11M | 0.04% | 392 |
|
|
2021
Q3 | $26.4M | Sell |
446,000
-286,000
| -39% | -$22.4M | 0.07% | 257 |
|
|
2021
Q2 | $63.5M | Sell |
732,000
-91,900
| -11% | -$7.41M | 0.17% | 123 |
|
|
2021
Q1 | $67.9M | Buy |
823,900
+225,631
| +38% | +$21.6M | 0.19% | 109 |
|
|
2020
Q4 | $54.4M | Buy |
598,269
+225,169
| +60% | +$14M | 0.15% | 153 |
|
|
2020
Q3 | $14.9M | Buy |
373,100
+218,500
| +141% | +$7.63M | 0.04% | 400 |
|
|
2020
Q2 | $5.3M | Buy |
154,600
+81,600
| +112% | +$2.43M | 0.02% | 768 |
|
|
2020
Q1 | $1.62M | Sell |
73,000
-83,200
| -53% | -$2.1M | 0.01% | 1223 |
|
|
2019
Q4 | $3.06M | Sell |
156,200
-53,300
| -25% | -$846K | 0.01% | 1038 |
|
|
2019
Q3 | $3.25M | Sell |
209,500
-48,200
| -19% | -$924K | 0.01% | 922 |
|
|
2019
Q2 | $5.23M | Sell |
257,700
-78,400
| -23% | -$1.41M | 0.01% | 811 |
|
|
2019
Q1 | $5.91M | Sell |
336,100
-20,600
| -6% | -$325K | 0.01% | 786 |
|
|
2018
Q4 | $4.58M | Buy |
356,700
+67,700
| +23% | +$944K | 0.01% | 834 |
|
|
2018
Q3 | $4.71M | Buy |
289,000
+87,900
| +44% | +$1.04M | 0.01% | 849 |
|
|
2018
Q2 | $2.28M | Buy |
201,100
+28,400
| +16% | +$313K | 0.01% | 1238 |
|
|
2018
Q1 | $1.69M | Buy |
172,700
+101,300
| +142% | +$970K | ﹤0.01% | 1325 |
|
|
2017
Q4 | $436K | Buy |
71,400
+51,400
| +257% | +$229K | ﹤0.01% | 1814 |
|
|
2017
Q3 | $79K | Buy |
+20,000
| New | +$68K | ﹤0.01% | 2132 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Two Sigma Advisers's FATE Position: Q1 2026 in Review
Two Sigma Advisers sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 1,651,700 shares — an estimated $1.62M sold.
Two Sigma Advisers first reported a position in FATE in Q3 2017 and held it in 34 quarters. The position peaked at $67.9M in Q1 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Two Sigma Advisers reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 1,651,700 Fate Therapeutics shares in Q1 2026, an estimated $1.62M.
- Two Sigma Advisers first reported a position in Fate Therapeutics in Q3 2017 and held it in 34 quarters.
- Two Sigma Advisers's Fate Therapeutics position peaked at $67.9M in Q1 2021.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.